Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

Annals of Oncology

Volumn 13, Issue 8, 2002, Pages 1285-1289

  Weidmann, E ^a   Kim, S Z ^a   Rost, A ^b   Schuppert, H ^b   Seipelt, G ^a   Hoelzer, D ^a   Mitrou, P S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KLINIKUM DARMSTADT   (Germany)

Author keywords

Aggressive lymphoma; Bendamustine; Refractory disease; Relapse

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; BENZIMIDAZOLE DERIVATIVE; CHLORMETHINE DERIVATIVE; GEMCITABINE; RITUXIMAB; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN ALLERGY; THROMBOCYTOPENIA; VOMITING; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036668672     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf189     Document Type: Article

References (16)

1. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure
2. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: A retrospective population-based study
3. Gemcitabine for relapsed or resistant lymphoma
4. Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
5. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma
6. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
7. Bendamustine
8. BOP versus COP in advanced low grade non-Hodgkin's lymphomas - Results of a randomized multicenter study
9. Bendamustine/prednisone versus melphalan/prednisone in the primary treatment of multiple myeloma: An updated analysis of the 94BP01 protocol
10. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study
11. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer
12. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphoma using combinations of established cytotoxic drugs with bendamustine
13. Weekly administration of bendamustine: A phase II study in patients with advanced progressive solid tumors
14. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
15. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
16. Treatment of non-Hodgkin's lymphoma